FMF: Many Trading Strategies, One TickerThis new ETF marks First Trust�� entrance into the world of Hedge Fund ETFs, which has grown considerably in the last few years as investors grow more comfortable with utilizing the exchange-traded product wrapper to access alternative asset classes. FMF looks to achieve positive returns that exceed the performance of its benchmark, the Morningstar Diversified Futures Index; this actively-managed fund works to achieve its objective be generating returns that are not directly correlated to broad market returns by employing long, short, and flat futures trading strategies to a basket of commodities, currencies and equities .�
Top 10 Bank Companies For 2015: Tetra Tech Inc.(TTEK)
Tetra Tech Inc., together with its subsidiaries, provides consulting, engineering, program management, construction management, and technical services for water, natural resources, environment, infrastructure, and energy sectors. The company operates in four segments: Engineering and Consulting Services (ECS), Technical Support Services (TSS), Engineering and Architecture Services (EAS), Remediation and Construction Management (RCM). The ECS segment offers front-end science, consulting engineering, and project management services in the areas of surface water management, groundwater, waste management, mining and geotechnical sciences, arctic engineering, industrial processes, and information technology. The TSS segment provides management consulting and strategic direction in the areas of environmental assessments/hazardous waste management, climate change, international development/stabilization, energy services, and technical government staffing services. The EAS segment offers engineering and architecture design services, including leadership in energy and environmental design (LEED) and sustainability services, together with technical and program administration services for projects related to water infrastructure, buildings, and transportation and facilities. The RCM segment provides environmental remediation, infrastructure development, and alternative energy services. The company offers its services to the U.S. federal, state, and local government agencies, as well as to commercial and international clients. Tetra Tech, Inc. was founded in 1966 and is headquartered in Pasadena, California.
Advisors' Opinion:- [By Rich Smith]
The Department of Defense awarded a dozen separate contracts Thursday, worth more than $225 million in aggregate. Notable winners (among publicly traded companies) included:
- [By Rich Smith]
The U.S. Department of Defense announced the award of 10 separate contracts Thursday, worth a bit over $340 million in aggregate value. Boeing and Raytheon claimed about one third of the money on offer, apiece. As for other companies participating in Pentagon funding, these included the following:
- [By Canadian Value]
Position % of Fund Assets 1) First American Financial Corp. (FAF) 7.0% 2) Apple, Inc. (AAPL) 6.5% 3) Coinstar, Inc. (CSTR) 4.8% 4) EMC Corp. (EMC) 4.4% 5) Coach, Inc. (COH) 4.4% 6) Kohl's Corp. (KSS) 4.1% 7) Blucora, Inc. (BCOR) 4.0% 8) Tetra Tech, Inc. (TTEK) 3.1% 9) OM Group, Inc. (OMG) 3.0% 10) American International Group, Inc. (AIG) 2.8% TOTAL 44.1% One area that we believe still offers some value in the market is in high quality, large��ap technology stocks that may be momentarily out��f��avor as they transition from rapid growth to slower growth. In particular, we become interested when that transition is also accompanied by a change in capital allocation policies designed to return more cash to shareholders in the form of dividends and share repurchases. We believe that Apple and EMC are two of the absolute highest quality technology businesses in the world and both have recently announced very material, shareholder��friendly changes to how they will allocate capital.
- [By Ben Levisohn]
URS Corp, which competes with the likes of Fluor (FLR), Jacobs Engineering (JEC) and Tetra Tech (TTEK), said it would earn between $3.20 and $3.30 a share in 2013–the previous range had been between $4.10 and $4.25 a share–and also offered guidance for 2014 that was well below analyst forecasts. On the plus side, URS said it would buy its shares back at a faster pace than previously announced.
Top 10 Sliver Companies To Watch In Right Now: Newport Corporation(NEWP)
Newport Corporation and its subsidiaries provide technology products and systems to scientific research, microelectronics, aerospace and defense/security, life and health sciences, and industrial markets in the United States, Europe, and the Pacific Rim. The company operates in three divisions: Photonics and Precision Technologies (PPT), Lasers, and Ophir. The PPT division provides photonics instruments and systems; vibration isolation systems and subsystems; precision positioning devices, systems, and subsystems; optics and optical hardware; opto-mechanical subassemblies and subsystems; and advanced manufacturing systems. It also offers automated systems for various applications in the manufacture of solar panels, and communications and electronic devices, including microwave, optical, radio frequency, and multi-chip modules. The Lasers division provides laser and laser-based system, such as ultrafast lasers and systems, diode-pumped solid state Q-switched lasers, diode-p umped solid state continuous wave (CW) and quasi-CW lasers, pulsed Nd:YAG and tunable lasers, and gas lasers. The Ophir division offers optics, photonics instruments, and three-dimensional non-contact measurement equipment and sensors. It also provides laser instrumentation, including laser power and energy meters, and laser beam profilers. This division serves the scientific research, microelectronics, aerospace, defense/security, life and health sciences, and industrial markets. The company offers its products under the ILX Lightwave, New Focus, Newport, Ophir, Optimet, Oriel Instruments, Richardson Gratings, Spiricon, and Spectra-Physics names. It sells its products to original equipment manufacturers and end-user customers through direct sales organizations, a network of independent distributors, and sales representatives, as well as through product catalogs and Web sites. Newport Corporation was founded in 1938 and is headquartered in Irvine, California.
Advisors' Opinion:- [By Brian Stoffel]
Rofin-Sinar (NASDAQ: RSTI ) , Coherent (NASDAQ: COHR ) , Newport (NASDAQ: NEWP ) , and JDS Uniphase (NASDAQ: JDSU ) all offer fiber-optic lasers as well.
- [By Evan Niu, CFA]
What: Shares of Newport (NASDAQ: NEWP ) got crushed today, down by as much as 12% after the company reported earnings that fell short of expectations.
Top 10 Sliver Companies To Watch In Right Now: Forest Laboratories Inc (FRX)
Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.
Aclidinium
In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
Linaclotide
Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.
Viibryd
As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.
Daliresp
In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Namenda
Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.
Bystolic
Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).
Savella
Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.
Teflaro
In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.
Avibactam
Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.
Lexapro
Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.
Cariprazine
Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.
Levomilnacipran
Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.
GRT 6005
In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.
TTP399
In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.
Azimilide
In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.
RGH-618
RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Tuesday morning, the healthcare sector proved to be a source of strength for the market. Healthcare stocks surged 1% in today's trading. Leading the sector was strength from Forest Laboratories (NYSE: FRX) and Chindex International (NASDAQ: CHDX) on acquisition news. - [By Keith Speights]
A bigger factor in the loss, though, was that sales and admin costs more than doubled during the first quarter. Ironwood and its partner Forest Labs (NYSE: FRX ) launched chronic constipation drug Linzess in December. Sales for the drug since its introduction to the market total around $24 million. Forest Labs says it expects Linzess to rack up $170 million in sales by the end of Q1 2014.
- [By Sean Williams]
Instead of Elan, I feel the struggling Forest Laboratories (NYSE: FRX ) would be the most qualified marketing partner to help Vascepa sales soar. Forest Labs is being hit hard by patent expirations, but would bring an experienced marketing staff to the table. In addition, it already has two FDA-approved cardiovascular drugs in Bystolic and Tiazac, which both work to treat high blood pressure. Partnering with Amarin would further strengthen its cardiovascular product offerings and help remove some of the marketing uncertainty and high costs currently plaguing Amarin's share price.
Top 10 Sliver Companies To Watch In Right Now: Kona Grill Inc.(KONA)
Kona Grill, Inc. owns and operates upscale casual dining restaurants in the United States. The company operates its restaurants under the Kona Grill name. As of September 22, 2011, it owned and operated 23 upscale casual restaurants in 16 states, including Arizona, Missouri, Nevada, Colorado, Nebraska, Indiana, Texas, Illinois, Michigan, Connecticut, Louisiana, Florida, Virginia, New Jersey, Minnesota, and Maryland. Kona Grill, Inc. was founded in 1994 and is based in Scottsdale, Arizona.
Advisors' Opinion:- [By Jon C. Ogg]
The 24/7 Wall St. list of public companies expected to double sales in the next few years includes the following: Kona Grill Inc. (NASDAQ: KONA), LinkedIn Corp. (NYSE: LNKD),�Noodles & Co. (NASDAQ: NDLS),�Onyx Pharmaceuticals Inc. (NASDAQ: ONXX),�Michael Kors Holdings Ltd. (NYSE: KORS),�Questcor Pharmaceuticals Inc. (NASDAQ: QCOR),�Tesla Motors Inc. (NASDAQ: TSLA),�Under Armour Inc. (NYSE: UA),�Workday Inc. (NYSE: WDAY) and Yelp Inc.�(NYSE: YELP). Facebook Inc. (NASDAQ: FB)�might as well be considered a runner-up here, but it was a direct competitor of LinkedIn in the selections.
- [By Quoth the Raven]
My argument here is very similar to my argument I recently made with Kona Grill (KONA). Not only is NGS similar to Kona in the fact that they both have insiders with a huge stake in the game, but they both have the same growth prospects.
- [By Lisa Levin]
Kona Grill (NASDAQ: KONA) shares rose 2.76% to reach a new 52-week high of $14.95. Kona Grill shares have jumped 66.10% over the past 52 weeks, while the S&P 500 index has gained 26.62% in the same period.
Top 10 Sliver Companies To Watch In Right Now: ProShares UltraShort Russell2000 (TWM)
ProShares UltraShort Russell2000 (the Fund) seeks daily investment results that correspond to twice (200%) the inverse (opposite) of the daily performance of the Russell 2000 Index (the Index). The Fund intends to invest at least 80% of its net assets, including any borrowings for investment purposes, to investments that, in combination, have economic characteristics that are inverse to those of the Index. The Fund also intends to invest assets not invested in financial instruments, in debt instruments and/or money market instruments. The Fund intends to concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. ProShare Advisors LLC serves as the investment advisor to the Fund. Advisors' Opinion:- [By Richard Rhodes]
We remain short, via a position, the Russell 200 2X Short (TWM) as well as short positions in Tesla (TSLA) and Chipolte (CMG).
Subscribe to The Rhodes Report here��/p>
Top 10 Sliver Companies To Watch In Right Now: Banco Santiago S.A.(SAN)
Banco Santander-Chile provides commercial and retail banking services to corporate and individual customers in Chile. The company offers time and demand deposits, checking accounts, and debit card accounts, as well as savings products; and peso and foreign currency denominated loans to finance various commercial transactions, trade, foreign currency forward contracts, and credit lines. Its loan portfolio comprises consumer loans, auto loans, residential mortgage loans, mutual funds, foreign trade financing, mortgage loans, and commercial loans. The company also provides factoring, credit cards, cash management, treasury services, short?term financing and funding, interest rate and foreign currency derivatives, and securitization services. Further, it offers various financial services, including leasing, financial leasing, financial advisory, mutual fund management, securities brokerage, insurance brokerage, and investment management services. As of December 31, 2010, the company had a branch network of 504 branches. Banco Santander-Chile was founded in 1977 and is headquartered in Santiago, Chile.
Advisors' Opinion:- [By Dan Carroll]
Spain's still mired in its crisis as unemployment surges, recently topping 27% for 2013's first quarter, with little hope of a major turnaround in sight. Still, some Spanish stocks have managed to push higher in 2013. While it hasn't matched the likes of the Dow's rise, Spanish financial firm Banco Santander (NYSE: SAN ) has seen shares rise more than 3.5% in 2013. The company's dealing with a recent CEO change, but between its high dividend that yields nearly 11% and its smart expansion into Latin American nations in order to mitigate European exposure, Santander's one of the best-positioned Spanish stocks for investors willing to take a gamble on picks in one of Europe's most beaten-down economies.
Top 10 Sliver Companies To Watch In Right Now: AutoNavi Holdings Limited(AMAP)
AutoNavi Holdings Limited provides digital map content, and navigation and location-based solutions in the People?s Republic of China (PRC). The company offers digital map data to various automobile manufacturers for in-dash navigation systems; and navigation solutions for use in in-dash navigation system to portable navigation device manufacturers based on their specific needs, which range from digital map data only to a digital map data, a navigation engine, and an user interface. It provides mobile/Internet location-based solutions to a mobile operator; mobile and Internet-based map application solutions that allow Web sites to embed location-based services capabilities into their Internet and enterprise applications; and MiniMap, an user-end map application software. The company also offers aerial digital maps and 3-D modeling applications to certain PRC government agencies and enterprises to meet their land usage survey, specific needs for 3-D geographic information, and other needs pursuant to a service contract arrangement. In addition, it has collaboration with certain mobile phone and tablet computer manufacturers and mobile operators to pre-install its navigation solutions. The company is headquartered in Beijing, China.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
AutoNavi Holdings (NASDAQ: AMAP) shot up 24.18 percent to $20.54 on Alibaba $21.00 per ADS offer.Shares of MannKind (NASDAQ: MNKD) were up as well, gaining 5.75 percent to $5.70 despite little news on the name during Monday's session.
- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Monday’s session are AutoNavi Holdings Ltd.(AMAP), Dick's Sporting Goods Inc.(DKS) and Supertex Inc.(SUPX)
No comments:
Post a Comment